Most therapies in development for Alzheimer’s are focused on changing disease biology, with targets ranging from amyloid pathology to inflammation. A leader of our clinical trials program shares an update on drug development and diagnostics.
Researchers have developed a personalized genomic medicine platform to identify clinically actionable mutations and accelerate the development of cancer precision medicine protocols.
Improvements in the cost and diagnostic accuracy of whole-exome and whole-genome sequencing are reshaping management of NICU patients. We explore benefits and barriers to use.
About 1 in 5 patients with dilated cardiomyopathy has an autoantibody subtype linked to a positive response to beta-blocker therapy. Here’s how that finding might translate to better-tailored treatment.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Physicians, scientists and advanced practice providers from virtually every medical specialty and scientific field heard their colleagues on the leading edge of this work highlight the hopes and challenges of precision medicine for the nearly 50 million people in the U.S. with disorders of immunity.